Global Launch – A New Pharma Initiative takes on the Antibiotic Innovation Challenge (Berlin)

Berlin, Germany

Acting now – public and private sector – shared goal to develop a robust pipeline of effective new antibiotics to safeguard our future.

The world is losing its most powerful tool in healthcare: antibiotics. The reason is rapidly rising antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The world needs new antibiotics to stem the toll superbugs are having on patients, but there are few in the pipeline. This is the result of a long-standing paradox: despite the huge societal costs of AMR, there is currently no viable market for new antibiotics. In the long run, the uncontrolled rise of AMR could have public health and economic consequences greater than COVID-19. But unlike COVID-19, AMR is a predictable and preventable crisis – we must take action now.

Launch events on 9 July from Berlin and Washington D.C and on 10 July from Tokyo.

Organized by IFPMA, EFPIA and VfA

14:30 to 15:10 CEST

PRESS CONFERENCE
• Hubertus von Baumbach, Chairman of the Board of Managing Directors, Boehringer Ingelheim
• Kasim Kutay, CEO, Novo Holdings
• Stefan Oelrich, Member of the Board of Management of Bayer AG and head of the Pharmaceuticals Division
• Stefan Oschmann, Chairman of the Executive Board and CEO of Merck
• Thomas Cueni, Director-General, IFPMA

15:15 to 17:00 CEST

LAUNCH EVENT
Introducing the new initiative – Bridging the gap between science and patients
– The problem, complication, and solution: Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
– The pharmaceutical industry investors:
o Hubertus von Baumbach, Chairman of the Board of Managing Directors, Boehringer Ingelheim
o Messages from: Emma Walmsley CEO GSK, Deborah Dunsire, President; CEO Lundbeck, Vas Narasimhan, CEO Novartis, Severin Schwan CEO Roche Group, Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson

The AMR public health challenge: Dame Sally Davies, UK Special Envoy on antimicrobial resistance (AMR)

Public health response to the initiative
– Dr Tedros Adhanom Ghebreyesus, Director General, World Health Organization
– Werner Hoyer, President, European Investment Bank
– Jeremy Farrar, Director, Wellcome Trust

PANEL: The inventor, investment and partnerships to bridge the gap
– Tiemo Wölken, MEP D German, vice-chair of European Parliament MEP Interest Group on AMR
– Florence Séjourné, CEO, Da Volterra and President BEAM Alliance
– Kasim Kutay, CEO, Novo Holdings
– Stefan Oelrich, Member of the Board of Management of Bayer AG and head of the Pharmaceuticals Division

PANEL: The world urgently needs new antibiotics – politics, leadership and public health

Health Ministers and the need for antibiotics innovation to tackle AMR
– Jens Spahn, Federal Minister of Health, Germany
– Magnus Heunicke, Minister of Health and Senior Citizens, Denmark
Joined by
– Agnès Pannier-Runacher Secretary of State for Economy and Finance, France
– Stella Kyriakides, European Commissioner for Health and Food Safety
– Stefan Oschmann, Chairman of the Executive Board and CEO of Merck
– Nathalie Moll, Director General, EFPIA

What’s in a name: launching the new initiative – Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)